This meta-analysis investigates the diagnostic performance  of non-contrast magnetic resonance imaging (MRI) for the detection of  hepatocellular carcinoma (HCC).
    A systematic review was performed to May 2020 for studies  that examined the diagnostic performance of non-contrast MRI (multi-sequence  or diffusion-weighted imaging (DWI)- alone) for HCC detection in high-risk  patients. The primary outcome was accuracy for the detection of HCC. Random  effects models were used to pool outcomes for sensitivity, specificity,  positive likelihood ratio (LR) and negative LR. Subgroup analyses for cirrhosis  and the size of the lesion were performed.
    The results of the study are as follows:
    Twenty-two studies were included involving 1685 patients for  per-patient analysis and 2128 lesions for per-lesion analysis. Multi-sequence  non-contrast MRI (NC-MRI) using T2+DWI±T1 sequences had a pooled per-patient  sensitivity of 86.8% (95%CI:83.9-89.4%), specificity of 90.3%  (95%CI:87.3-92.7%), and negative LR of 0.17 (95%CI:0.14-0.20). DWI-only MRI  (DW-MRI) had a pooled sensitivity of 79.2% (95%CI:71.8-85.4%), specificity of  96.5% (95%CI:94.3-98.1%) and negative LR of 0.24 (95%CI:1.62-0.34). In patients  with cirrhosis, NC-MRI had a pooled per-patient sensitivity of 87.3%  (95%CI:82.7-91.0%) and specificity of 81.6% (95%CI:75.3-86.8%), whilst DWI-MRI  had a pooled sensitivity of 71.4% (95%CI:60.5-80.8%) and specificity of 97.1%  (95%CI:91.9-99.4%). For lesions <2 cm, the pooled per-lesion sensitivity was  77.1% (95%CI:73.8-80.2%). For lesions >2 cm, pooled per-lesion sensitivity  was 88.5% (95%CI:85.0-91.5%).
    Thus, the researchers concluded that non-contrast MRI has a  moderate negative LR and high specificity with acceptable sensitivity for the  detection of HCC, even in patients with cirrhosis and with lesions <2 cm.  Prospective trials to validate if non-contrast MRI can be used for HCC  surveillance is warranted.
    Reference:
    Noncontrast MRI for Hepatocellular Carcinoma Detection: A  Systematic Review and Meta-analysis – A Potential Surveillance Tool? By Michael  Vinchill Chan et al. published in the Clinical Gastroenterology and Hepatology
    https://www.cghjournal.org/article/S1542-3565(21)00215-9/fulltext  
 
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.